Related Experiment Video
Updated: Jan 17, 2026
Fabrication and Implantation of Miniature Dual-element Strain Gages for Measuring In Vivo Gastrointestinal Contractions in Rodents.
Published on: September 18, 2014
Effects of Improved Sleep and Gastric Vagotomy on Serum Inflammatory Mediators in Peptic Ulcer Rats
Huang Du1, Lianxiang Peng2, Guohua Gong2
1Department of Gastroenterology, Minqing County General Hospital, Fuzhou, Fujian Province, China.
Objective:
Vagotomy is a method used to treat peptic ulcers, but its mechanism of action in terms of inflammatory mediators and neurophysiology remains unclear. This study investigates the effects of vagotomy and improved sleep on serum inflammatory mediators in rats.
Methods:
One hundred and eighty healthy rats were allocated into five groups, each consisting of 36 rats: control, sleep disturbance, ulcer, improved sleep and vagotomy. They underwent various treatments, including sleep deprivation, ulcer induction with acetic acid, and vagotomy. We measured gastric vagal nerve activity, gastric acid secretion, and serum inflammatory mediators (IL-1β, IL-6, IL-8, TNF-α), comparing these parameters across groups.
Results:
Gastric acid secretion was elevated in the sleep disturbance and ulcer group but decreased in the improved sleep group (p < 0.01). Gastric vagal nerve activity was heightened in the sleep disturbance and ulcer group, with some improvement in the improved sleep group. Serum inflammatory mediators' mRNA expression was increased in both the ulcer and sleep disturbance group, while it decreased in the improved sleep and vagotomy group (p < 0.01). The vagotomy group showed no significant inflammation in the gastric mucosa, while some recovery was observed in the ulcer area's mucosa in the improved sleep group.
Conclusion:
Improved sleep can enhance vagal nerve excitability, decrease inflammatory mediator release, and support the healing of peptic ulcers.
Related Concept Videos
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...